Cargando…

COVID-19 vaccine effectiveness among people living with and without HIV in South Carolina, USA: protocol of a population-based cohort study

INTRODUCTION: Despite the effectiveness of COVID-19 vaccines in preventing severe COVID-19 outcomes, a small percentage of fully vaccinated persons will develop symptomatic or asymptomatic infections with SARS-CoV-2, which is referred to as ‘breakthrough COVID-19’. People living with HIV (PLWH) appe...

Descripción completa

Detalles Bibliográficos
Autores principales: Yang, Xueying, Zhang, Jiajia, Olatosi, Bankole, Weissman, Sharon, Li, Xiaoming
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9402448/
https://www.ncbi.nlm.nih.gov/pubmed/35998950
http://dx.doi.org/10.1136/bmjopen-2022-067095
_version_ 1784773179442462720
author Yang, Xueying
Zhang, Jiajia
Olatosi, Bankole
Weissman, Sharon
Li, Xiaoming
author_facet Yang, Xueying
Zhang, Jiajia
Olatosi, Bankole
Weissman, Sharon
Li, Xiaoming
author_sort Yang, Xueying
collection PubMed
description INTRODUCTION: Despite the effectiveness of COVID-19 vaccines in preventing severe COVID-19 outcomes, a small percentage of fully vaccinated persons will develop symptomatic or asymptomatic infections with SARS-CoV-2, which is referred to as ‘breakthrough COVID-19’. People living with HIV (PLWH) appear to have an elevated risk of severe COVID-19 outcomes, yet the effectiveness of the COVID-19 vaccine in this population remains unclear due to the limited research efforts in this population in the real world. This study aims to characterise and compare the breakthrough COVID-19 (eg, prevalence and disease severity) between PLWH and non-PLWH and then examine whether HIV markers play a role in COVID-19 vaccine effectiveness within the PLWH population. METHODS AND ANALYSIS: This cohort study will merge electronic health records data from multiple data sources in South Carolina (SC), including the ‘HIV Cohort’ (n=12 203) identified from the statewide Enhanced HIV/AIDS Reporting System, ‘Vaccine Cohort’ from the Statewide Immunisation Online Network which provides patient-level immunisation records (n=~1.71 million), and ‘COVID-19 Cohort’ which includes healthcare encounters and COVID-19 diagnosis information for all individuals who were tested for COVID-19 (n=~3.41 million). The PLWH will be matched with a comparison group of non-PLWH by the propensity score matching method. To distinguish the role of immunity level in affecting the vaccine effectiveness, we will conduct subgroup analyses to compare the outcome of virally controlled and immunosuppressed PLWH with non-PLWH. Conditional logistic regression and generalised linear models will be employed to analyse the relationship between HIV status and protection durability by adjusting for potential confounders. ETHICS AND DISSEMINATION: The study was approved by the Institutional Review Board at the University of South Carolina (Pro00117583) as a Non-Human Subject study. The study’s findings will be published in peer-reviewed journals and disseminated at national and international conferences and through social media.
format Online
Article
Text
id pubmed-9402448
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-94024482022-08-25 COVID-19 vaccine effectiveness among people living with and without HIV in South Carolina, USA: protocol of a population-based cohort study Yang, Xueying Zhang, Jiajia Olatosi, Bankole Weissman, Sharon Li, Xiaoming BMJ Open HIV/AIDS INTRODUCTION: Despite the effectiveness of COVID-19 vaccines in preventing severe COVID-19 outcomes, a small percentage of fully vaccinated persons will develop symptomatic or asymptomatic infections with SARS-CoV-2, which is referred to as ‘breakthrough COVID-19’. People living with HIV (PLWH) appear to have an elevated risk of severe COVID-19 outcomes, yet the effectiveness of the COVID-19 vaccine in this population remains unclear due to the limited research efforts in this population in the real world. This study aims to characterise and compare the breakthrough COVID-19 (eg, prevalence and disease severity) between PLWH and non-PLWH and then examine whether HIV markers play a role in COVID-19 vaccine effectiveness within the PLWH population. METHODS AND ANALYSIS: This cohort study will merge electronic health records data from multiple data sources in South Carolina (SC), including the ‘HIV Cohort’ (n=12 203) identified from the statewide Enhanced HIV/AIDS Reporting System, ‘Vaccine Cohort’ from the Statewide Immunisation Online Network which provides patient-level immunisation records (n=~1.71 million), and ‘COVID-19 Cohort’ which includes healthcare encounters and COVID-19 diagnosis information for all individuals who were tested for COVID-19 (n=~3.41 million). The PLWH will be matched with a comparison group of non-PLWH by the propensity score matching method. To distinguish the role of immunity level in affecting the vaccine effectiveness, we will conduct subgroup analyses to compare the outcome of virally controlled and immunosuppressed PLWH with non-PLWH. Conditional logistic regression and generalised linear models will be employed to analyse the relationship between HIV status and protection durability by adjusting for potential confounders. ETHICS AND DISSEMINATION: The study was approved by the Institutional Review Board at the University of South Carolina (Pro00117583) as a Non-Human Subject study. The study’s findings will be published in peer-reviewed journals and disseminated at national and international conferences and through social media. BMJ Publishing Group 2022-08-23 /pmc/articles/PMC9402448/ /pubmed/35998950 http://dx.doi.org/10.1136/bmjopen-2022-067095 Text en © Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) .
spellingShingle HIV/AIDS
Yang, Xueying
Zhang, Jiajia
Olatosi, Bankole
Weissman, Sharon
Li, Xiaoming
COVID-19 vaccine effectiveness among people living with and without HIV in South Carolina, USA: protocol of a population-based cohort study
title COVID-19 vaccine effectiveness among people living with and without HIV in South Carolina, USA: protocol of a population-based cohort study
title_full COVID-19 vaccine effectiveness among people living with and without HIV in South Carolina, USA: protocol of a population-based cohort study
title_fullStr COVID-19 vaccine effectiveness among people living with and without HIV in South Carolina, USA: protocol of a population-based cohort study
title_full_unstemmed COVID-19 vaccine effectiveness among people living with and without HIV in South Carolina, USA: protocol of a population-based cohort study
title_short COVID-19 vaccine effectiveness among people living with and without HIV in South Carolina, USA: protocol of a population-based cohort study
title_sort covid-19 vaccine effectiveness among people living with and without hiv in south carolina, usa: protocol of a population-based cohort study
topic HIV/AIDS
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9402448/
https://www.ncbi.nlm.nih.gov/pubmed/35998950
http://dx.doi.org/10.1136/bmjopen-2022-067095
work_keys_str_mv AT yangxueying covid19vaccineeffectivenessamongpeoplelivingwithandwithouthivinsouthcarolinausaprotocolofapopulationbasedcohortstudy
AT zhangjiajia covid19vaccineeffectivenessamongpeoplelivingwithandwithouthivinsouthcarolinausaprotocolofapopulationbasedcohortstudy
AT olatosibankole covid19vaccineeffectivenessamongpeoplelivingwithandwithouthivinsouthcarolinausaprotocolofapopulationbasedcohortstudy
AT weissmansharon covid19vaccineeffectivenessamongpeoplelivingwithandwithouthivinsouthcarolinausaprotocolofapopulationbasedcohortstudy
AT lixiaoming covid19vaccineeffectivenessamongpeoplelivingwithandwithouthivinsouthcarolinausaprotocolofapopulationbasedcohortstudy